Guardant Health, Inc.·4

Mar 5, 5:44 PM ET

Kalia Kumud 4

4 · Guardant Health, Inc. · Filed Mar 5, 2026

Insider Transaction Report

Form 4
Period: 2026-03-04
Kalia Kumud
Chief Information Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-03-04$47.20/sh+2,119$100,01736,643 total
  • Exercise/Conversion

    Common Stock

    2026-03-04$47.20/sh+15,000$708,00051,643 total
  • Exercise/Conversion

    Common Stock

    2026-03-04$74.00/sh+1,000$74,00052,643 total
  • Exercise/Conversion

    Common Stock

    2026-03-04$32.86/sh+5,000$164,30057,643 total
  • Exercise/Conversion

    Common Stock

    2026-03-04$28.37/sh+10,000$283,70067,643 total
  • Exercise/Conversion

    Common Stock

    2026-03-04$28.61/sh+10,000$286,10077,643 total
  • Sale

    Common Stock

    [F1]
    2026-03-04$95.12/sh26,980$2,566,31150,663 total
  • Sale

    Common Stock

    [F2]
    2026-03-04$95.73/sh13,020$1,246,35037,643 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F3]
    2026-03-042,11949,305 total
    Exercise: $47.20Exp: 2032-11-07Common Stock (2,119 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F3]
    2026-03-0415,00034,305 total
    Exercise: $47.20Exp: 2032-11-07Common Stock (15,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F4]
    2026-03-041,00027,670 total
    Exercise: $74.00Exp: 2030-04-20Common Stock (1,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F5]
    2026-03-045,0006,414 total
    Exercise: $32.86Exp: 2033-06-09Common Stock (5,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F6]
    2026-03-0410,0009,410 total
    Exercise: $28.37Exp: 2033-12-13Common Stock (10,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F7]
    2026-03-0410,00025,721 total
    Exercise: $28.61Exp: 2034-11-08Common Stock (10,000 underlying)
Footnotes (7)
  • [F1]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.460 to $95.455. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F2]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $95.46 to $96.14. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]This represents a stock option award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on November 7, 2023 and the remaining 75% of the shares vests in equal monthly installments over the remaining three-year period thereafter.
  • [F4]This represents a stock option award granted on April 20, 2020 that vests over a four-year period. 25% of the shares subject to such award vested on January 7, 2021 and the remaining 75% of the shares vested in equal monthly installments over the three-year period thereafter.
  • [F5]This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 9, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
  • [F6]This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
  • [F7]This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
Signature
/s/ John G. Saia, as attorney-in-fact for Kumud Kalia|2026-03-05

Documents

1 file
  • 4
    wk-form4_1772750655.xmlPrimary

    FORM 4